Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection

References

• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021 Jan;128(1):89–99. Epub 2020 Jun 20. PMID: 32574761. doi:10.1016/j.ophtha.2020.06.028.
   PubMed Web of Science ®Google Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020 Oct;127(10):1345–1359. Epub 2020 Apr 25. PMID: 32344075. doi:10.1016/j.ophtha.2020.04.017.
   PubMed Web of Science ®Google Scholar
• Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2020 Nov 15;S0161-6420(20):31075–31077. Epub ahead of print. PMID: 33207259. doi:10.1016/j.ophtha.2020.11.011.
   Google Scholar
• Sharma A, Kumar N, Parachuri N, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam’s razor? Ocul Immunol Inflamm. 2021 May 20;1-3. ( Epub ahead of print. PMID: 34014141). doi:10.1080/09273948.2021.1897628.
   Google Scholar
• Haug SJ, Hien DL, Uludag G, et al., Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. Mar 31, 2020;18:100680. PMID: 32258827; PMCID: PMC7125319. doi:10.1016/j.ajoc.2020.100680.
   PubMedGoogle Scholar
• Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. Nov 10, 2020;20:100989. PMID: 33294727; PMCID: PMC7695942. doi:10.1016/j.ajoc.2020.100989.
   PubMedGoogle Scholar
• Anderson WJ, Da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of anti-angiogenic drugs: a narrative review. Int J Retina Vitreous. 2021 May 7;7(1):37. PMID: 33962696; PMCID: PMC8103589. doi:10.1186/s40942-021-00307-7.
   PubMedGoogle Scholar
• Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med. 2021 Mar 2;10(5):981. PMID: 33801185; PMCID: PMC7957879. doi:10.3390/jcm10050981.
   PubMed Web of Science ®Google Scholar
• Iyer PG, Albini TA. Drug-related adverse effects of anti-vascular endothelial growth factor agents. Curr Opin Ophthalmol. 2021 May 1;32(3):191–197. PMID: 33770015. doi:10.1097/ICU.0000000000000757.
   PubMed Web of Science ®Google Scholar
• Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraokulare Entzündungen bei Brolucizumab-Anwendung: patientenmanagement – diagnose – therapie. Ophthalmologe. 2021 Mar;118(3):248–256. Epub 2021 Feb 8. PMID: 33555415; PMCID: PMC7935813. doi:10.1007/s00347-021-01321-8.
   PubMedGoogle Scholar
• Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2020 Sep 29; S2468-6530(20):30400–0. Epub ahead of print. PMID: 33007521. doi:10.1016/j.oret.2020.09.020.
   Google Scholar
• Ip M, Albini T, Zarbin M, et al. The brolucizumab experience thus far: a health economics and outcomes research analysis. AAO Annual Meeting, 13-15 November 2020 Virtual meeting.
   Google Scholar
• Singer M, Albini TA, Seres A, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2021 May 7; S2468-6530(21):00162–7. Epub ahead of print. PMID: 33971353. doi:10.1016/j.oret.2021.05.003.
   Google Scholar
• Eskandarpour M, Nunn MA, Weston-Davies W, Calder VL. Immune-mediated retinal vasculitis in posterior uveitis and experimental models: the leukotriene (LT)B4-VEGF axis. Cells. 2021 Feb 15;10(2):396. PMID: 33671954; PMCID: PMC7919050. doi:10.3390/cells10020396.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M. Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res. 2008 Jan;27(1):111–136. Epub 2007 Nov 26. PMID: 18035584. doi:10.1016/j.preteyeres.2007.09.002.
   PubMed Web of Science ®Google Scholar
• Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the anti-phospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol. 2004 Feb;32(1):87–100. PMID: 14746601. doi:10.1046/j.1442-9071.2004.00766.x.
   PubMed Web of Science ®Google Scholar
• Ksiaa I, Abroug N, Kechida M, et al. Eye and Behçet’s disease. J Fr Ophtalmol. 2019 Apr;42(4):e133–e146. Epub 2019 Mar 5. PMID: 30850197. doi:10.1016/j.jfo.2019.02.002.
   PubMed Web of Science ®Google Scholar
• De Lott LB, Burke JF, Andrews CA, et al. Association of individual-level factors with visual outcomes in optic neuritis: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2020 May 1;3(5):e204339. PMID: 32379333; PMCID: PMC7206503. doi: 10.1001/jamanetworkopen.2020.4339.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993 Jun;111(6):773–775. PMID: 8512477. doi:10.1001/archopht.1993.01090060061023.
   PubMedGoogle Scholar
• Mohammadi M, Shahram F, Shams H, Akhlaghi M, Ashofteh F, Davatchi F. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet’s disease: a pilot double-blind controlled study. Int J Rheum Dis. 2017 Sep;20(9):1269–1276. Epub 2017 May 19. PMID: 28524639. doi:10.1111/1756-185X.13095.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Horiguchi E, Kawano K, et al. Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. Jpn J Ophthalmol. 2021 Mar;65(2):199–207. PMID: 33543352. doi:10.1007/s10384-021-00818-8.
   PubMed Web of Science ®Google Scholar
• Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J Ophthalmol. 2014;2014:197675. doi:10.1155/2014/197675.
   PubMed Web of Science ®Google Scholar